Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McGill University
$120,000.00
From Imbalance to Equilibrium: Antisense Oligonucleotide Therapy Targeting Allelic Imbalance in PEX6 Zellweger Spectrum Disorder
EF 2025-26
Résumé
Zellweger Spectrum Disorder (ZSD) is a rare inherited disease caused by defects in genes required for peroxisomes, which are small compartments in every cell that carry out essential metabolic functions. People with ZSD may experience serious symptoms such as developmental delay, liver disease, and vision and hearing loss. Currently, there is no cure for ZSD, and treatment is limited to symptom management. Our project aims to develop a new treatment for ZSD caused by changes in the PEX6 gene, one of the most common causes of the disorder. A subset of patients was recently identified with an unusual form of ZSD, where the defective gene copy is more active than the healthy one. This imbalance reduces the benefit of the healthy copy of the gene and worsens disease symptoms. We are developing a type of RNA-based drug, called an antisense oligonucleotide (ASO), designed to restore balance between the healthy and defective gene copies. By rebalancing activity toward the healthier copy, we hope to improve peroxisome function and lessen symptoms. Importantly, this gene imbalance is predicted to affect more than one-third of people with PEX6-related ZSD. If successful, our approach could provide the first targeted treatment for this condition and may also serve as a model for treating other genetic disorders caused by similar gene imbalances.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
560264
Name
Zavacky Evelyn M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
From Imbalance to Equilibrium: Antisense Oligonucleotide Therapy Targeting Allelic Imbalance in PEX6 Zellweger Spectrum Disorder
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cell Biology; Molecular Biology; Patient Fibroblasts; Peroxisomal Disorders; Personalized Therapy; Regulatory Genetics; Rna Therapy
Abstract
Zellweger Spectrum Disorder (ZSD) is a rare inherited disease caused by defects in genes required for peroxisomes, which are small compartments in every cell that carry out essential metabolic functions. People with ZSD may experience serious symptoms such as developmental delay, liver disease, and vision and hearing loss. Currently, there is no cure for ZSD, and treatment is limited to symptom management. Our project aims to develop a new treatment for ZSD caused by changes in the PEX6 gene, one of the most common causes of the disorder. A subset of patients was recently identified with an unusual form of ZSD, where the defective gene copy is more active than the healthy one. This imbalance reduces the benefit of the healthy copy of the gene and worsens disease symptoms. We are developing a type of RNA-based drug, called an antisense oligonucleotide (ASO), designed to restore balance between the healthy and defective gene copies. By rebalancing activity toward the healthier copy, we hope to improve peroxisome function and lessen symptoms. Importantly, this gene imbalance is predicted to affect more than one-third of people with PEX6-related ZSD. If successful, our approach could provide the first targeted treatment for this condition and may also serve as a model for treating other genetic disorders caused by similar gene imbalances.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zavacky, Evelyn M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~